Formoso Technologies

Formoso Technologies is a pre-clinical stage biotechnology company focused on overcoming the fundamental challenges of oral biologic delivery. Spun out of the laboratories of Robert Langer and Giovanni Traverso at MIT, the company utilizes a proprietary platform designed to protect large molecules from degradation in the gastrointestinal tract while enhancing their absorption into the bloodstream. Their primary mission is to transform traditionally injectable therapies, such as insulin and GLP-1 receptor agonists, into convenient oral formulations. By improving patient compliance and expanding access to life-changing biologics, Formoso aims to redefine the treatment landscape for chronic conditions like diabetes and obesity. The company's technology leverages advanced material science to navigate the complex environment of the small intestine.